Minimally invasive and non-surgical treatments for HF
This article was originally published in Start Up
The most prevalent kind of heart failure is caused by heart attack damage to the left ventricle, and the standard treatment is an open-heart procedure called surgical ventricular restoration. BioVentrix Inc. aims to replace SVR with a less invasive version of the procedure, using its Revivent Myocardial Anchoring System, designed to pull the damaged segments of the left ventricle together to reduce the burden on the non-damaged myocardium and improve its performance.
You may also be interested in...
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.
Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.